Patents Assigned to Senex Biotechnology
  • Patent number: 12281080
    Abstract: Disclosed herein are quinoline-based compounds and method for inhibiting CDK8 or CDK19 for the intervention in diseases, disorders, and conditions. The quinoline-based composition comprise substituents at quinoline ring positions 4 and 6, wherein the substituent at position 4 is selected from a substituted or unsubstituted arylalkylamine or a substituted or unsubstituted arylhetrocyclylamine. Pharmaceutical compositions comprising the substituted quinoline compositions, methods of inhibiting CDK8 or CDK19, and methods of treating CDK8/19-associated diseases, disorders, or conditions are also disclosed.
    Type: Grant
    Filed: May 25, 2021
    Date of Patent: April 22, 2025
    Assignees: University of South Carolina, Senex Biotechnology, Inc.
    Inventors: Igor Roninson, Campbell McInnes, Mengqian Chen, Li Zhang, Jing Li
  • Publication number: 20210322651
    Abstract: The invention provides methods for suppressing neointimal formation resulting from vascular surgery, comprising administering to a patient having vascular surgery one or more inhibitors of CDK8/19.
    Type: Application
    Filed: December 18, 2015
    Publication date: October 21, 2021
    Applicant: Senex Biotechnology, Inc.
    Inventors: Igor B. Roninson, Taixing Cui
  • Publication number: 20210276956
    Abstract: Disclosed herein are quinoline-based compounds and method for inhibiting CDK8 or CDK19 for the intervention in diseases, disorders, and conditions. The quinoline-based composition comprise substituents at quinoline ring positions 4 and 6, wherein the substituent at position 4 is selected from a substituted or unsubstituted arylalkylamine or a substituted or unsubstituted arylhetrocyclylamine. Pharmaceutical compositions comprising the substituted qunioline compositions, methods of inhibiting CDK8 or CDK19, and methods of treating CDK8/19-associated diseases, disorders, or conditions are also disclosed.
    Type: Application
    Filed: May 25, 2021
    Publication date: September 9, 2021
    Applicants: University of South Carolina, Senex Biotechnology, Inc.
    Inventors: Igor Roninson, Campbell McInnes, Mengqian Chen, Li Zhang, Jing Li
  • Patent number: 11014906
    Abstract: Disclosed herein are quinoline-based compounds and method for inhibiting CDK8 or CDK19 for the intervention in diseases, disorders, and conditions. The quinoline-based composition comprise substituents at quinoline ring positions 4 and 6, wherein the substituent at position 4 is selected from a substituted or unsubstituted arylalkylamine or a substituted or unsubstituted arylhetrocyclylamine. Pharmaceutical compositions comprising the substituted quinoline compositions, methods of inhibiting CDK8 or CDK19, and methods of treating CDK8/19-associated diseases, disorders, or conditions are also disclosed.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: May 25, 2021
    Assignees: University of South Carolina, Senex Biotechnology, Inc.
    Inventors: Igor Roninson, Campbell McInnes, Mengqian Chen, Li Zhang, Jing Li
  • Patent number: 10584369
    Abstract: The invention provides a method for determining the activity of an inhibitor of a target protein that has a deleterious effect on cell growth. The principle of the claimed method is that a compound that inhibits the function of an overexpressed protein will relieve the detrimental effect of such overexpression in a concentration-dependent manner, thereby allowing the determination of the activity of the compound in inhibiting its target protein in live cells.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: March 10, 2020
    Assignee: Senex Biotechnology, Inc.
    Inventors: Igor B Roninson, Donald C Porter, Serena Altilia
  • Publication number: 20200062728
    Abstract: Disclosed herein are quinoline-based compounds and method for inhibiting CDK8 or CDK19 for the intervention in diseases, disorders, and conditions. The quinoline-based composition comprise substituents at quinoline ring positions 4 and 6, wherein the substituent at position 4 is selected from a substituted or unsubstituted arylalkylamine or a substituted or unsubstituted arylhetrocyclylamine. Pharmaceutical compositions comprising the substituted qunioline compositions, methods of inhibiting CDK8 or CDK19, and methods of treating CDK8/19-associated diseases, disorders, or conditions are also disclosed.
    Type: Application
    Filed: August 21, 2019
    Publication date: February 27, 2020
    Applicants: University of South Carolina, Senex Biotechnology, Inc.
    Inventors: Igor Roninson, Campbell McInnes, Mengqian Chen, Li Zhang, Jing Li
  • Publication number: 20200048208
    Abstract: The invention provides a method for treating a disease or disorder in a mammal which is caused by induced NFkB transcriptional activity in cells of the mammal, the method comprising administering to the mammal a compound that specifically inhibits one or more of CDK8 and CDK19.
    Type: Application
    Filed: August 23, 2019
    Publication date: February 13, 2020
    Applicant: Senex Biotechnology, Inc.
    Inventors: Donald C. PORTER, Igor B. RONINSON
  • Patent number: 8598344
    Abstract: The invention relates to compounds for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: December 3, 2013
    Assignee: Senex Biotechnology
    Inventors: Donald C. Porter, Igor B. Roninson, Mark P. Wentland
  • Patent number: 8592147
    Abstract: The invention relates to methods for high-throughput screening for compounds that modulate cell growth or promoter activity. The invention provides the use of cell lines with properly regulated promoter-reporter expression, suitable for high-throughput screening. More particularly, the invention relates to such screening to identify compounds that affect cell growth and/or that modulate the effect of cell cycle arrest on the function of a promoter that is responsive to cell cycle inhibition.
    Type: Grant
    Filed: January 12, 2006
    Date of Patent: November 26, 2013
    Assignee: Senex Biotechnology
    Inventors: Bey-Dih Chang, Igor B. Roninson
  • Publication number: 20120071477
    Abstract: The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases.
    Type: Application
    Filed: November 30, 2010
    Publication date: March 22, 2012
    Applicant: Senex Biotechnology, Inc.
    Inventors: Donald C. Porter, Igor B. Roninson, Mark P. Wentland